<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J. Neurol</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5808094</article-id><article-id pub-id-type="publisher-id">8641</article-id><article-id pub-id-type="doi">10.1007/s00415-017-8641-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advances in understanding nociception and neuropathic pain</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2699-1979</contrib-id><name><surname>St. John Smith</surname><given-names>Ewan</given-names></name><address><phone>+44 1223 334048</phone><email>es336@cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Department of Pharmacology, </institution><institution>University of Cambridge, </institution></institution-wrap>Tennis Court Road, Cambridge, CB2 1PD UK </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>265</volume><issue>2</issue><fpage>231</fpage><lpage>238</lpage><history><date date-type="received"><day>14</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>2</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Pain results from the activation of a subset of sensory neurones termed nociceptors and has evolved as a &#x0201c;detect and protect&#x0201d; mechanism. However, lesion or disease in the sensory system can result in neuropathic pain, which serves no protective function. Understanding how the sensory nervous system works and what changes occur in neuropathic pain are vital in identifying new therapeutic targets and developing novel analgesics. In recent years, technologies such as optogenetics and RNA-sequencing have been developed, which alongside the more traditional use of animal neuropathic pain models and insights from genetic variations in humans have enabled significant advances to be made in the mechanistic understanding of neuropathic pain.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chemogenetics</kwd><kwd>Neurocircuitry</kwd><kwd>Neuropathic pain</kwd><kwd>Nociceptor</kwd><kwd>Optogenetics</kwd><kwd>Voltage gated sodium channel (NaV)</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000341</institution-id><institution>Arthritis Research UK</institution></institution-wrap></funding-source><award-id>20930</award-id><principal-award-recipient><name><surname>St. John Smith</surname><given-names>Ewan</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000833</institution-id><institution>Rosetrees Trust</institution></institution-wrap></funding-source><award-id>A1296</award-id><principal-award-recipient><name><surname>St. John Smith</surname><given-names>Ewan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Nociception is the neural process of encoding noxious stimuli, whereas pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage [<xref ref-type="bibr" rid="CR1">1</xref>]. Nociception has been described in a variety of organisms, from the nematode worm <italic>Caenorhabditis elegans</italic> through to humans, but the case for pain is less clear. Although humans and likely all mammals experience negative emotion, this is considered unlikely in <italic>C. elegans</italic>, but the case for certain organisms, especially fish, is more contentious [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Numerous reviews have been written about different aspects of pain, from its molecular basis [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>] and genetic mechanisms [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>] to its pharmacological treatment [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. The purpose of this review is to discuss how recent insights into pain mechanisms from pre-clinical research may lead to breakthroughs in our understanding, and hopefully treatment, of chronic pain.</p><p id="Par3">Chronic pain is usually defined as regularly occurring pain over a period of several months and it has a prevalence of&#x000a0;~11&#x02013;19% of the adult population [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Broadly speaking, chronic pain can be split into two categories, inflammatory pain and neuropathic pain. Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system and a systematic review of epidemiological studies estimates the prevalence of neuropathic pain to be 6.9&#x02013;10% [<xref ref-type="bibr" rid="CR20">20</xref>]. The need for novel therapies to treat neuropathic pain is demonstrated by the analysis of analgesia success. A 2006 report on chronic pain in Europe identified that 64% of those taking prescription medicine found that their pain medication was at times inadequate, and of the 48% of chronic pain sufferers not taking pain medication, 14% had stopped due to side effects [<xref ref-type="bibr" rid="CR18">18</xref>]. To develop new treatments for neuropathic pain, it is important to first understand the circuitry of pain: how is pain triggered and how is that information transmitted to the central nervous system? To do this, it is necessary to understand how nociceptors function.</p></sec><sec id="Sec2"><title>Nociceptors: transducers of pain</title><p id="Par4">The human body is equipped with different types of sensory neurones and nociceptors are the subset that function as the primary unit of pain, being equipped with receptors and ion channels that enable the detection of stimuli that have potential to cause damage. When a noxious stimulus activates an ion channel on a nociceptor, for example proton activation of acid-sensing ion channels (ASIC), cation influx depolarises the nociceptor producing a receptor potential. If the receptor potential is of sufficient magnitude to reach the activation threshold for voltage-gated Na<sup>+</sup> channels (NaV), it will trigger action potential generation and transmission of a pain signal to the spinal cord [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In recent years, many new techniques have been developed in pre-clinical research that have accelerated our progress in understanding how nociceptors work and provide tantalising glimpses at their clinical utility. Indeed, such work is essential for both identifying potential new painkiller targets and the developing novel biological treatments for neuropathic pain.</p><sec id="Sec3"><title>Nociceptor functionality</title><p id="Par5">Anatomical and in vivo/in vitro electrophysiological data show that some nociceptors are myelinated A&#x003b4;-fibres and that others are unmyelinated C-fibres, different subsets of which are sensitive to a different range of stimuli, most being polymodal, but others responding to a narrower range of stimuli [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Recent developments in transgenic mouse and imaging technology have led to elegant in vivo experiments using the genetically encoded Ca<sup>2+</sup>-indicator GCaMP [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>], the fluorescence intensity of which is proportional to intracellular [Ca<sup>2+</sup>]. In contrast to electrophysiological studies, which suggest a predominantly polymodal nociceptor phenotype, some GCaMP studies have found that under control conditions, most sensory neurones in vivo are actually modality-specific, i.e., they respond to a single noxious stimulus, such as mechanical pinch of the hind paw, but not extreme heat or cold [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, like previous electrophysiology studies, in vivo GCaMP studies have found that injury and inflammation produce increased neuronal responsiveness [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]; the increased excitability of sensory neurones observed after injury is likely a key driver of both spontaneous and stimulus-evoked pain experienced by neuropathic pain patients. The discord between electrophysiological and GCaMP studies has been suggested to arise from the invasiveness of in vivo electrophysiological approaches and the trauma of dissociation required for in vitro analysis, both of which may induce inflammation contributing to the induction of nociceptor polymodality [<xref ref-type="bibr" rid="CR22">22</xref>]. Although a technique that enables simultaneous measurement of multiple sensory neurones, in vivo measurement of intracellular [Ca<sup>2+</sup>] is, however, an indirect method of measuring action potential firing, i.e., signal conduction: not every action potential in a primary afferent fibre necessarily produces a measurable change in intracellular [Ca<sup>2+</sup>] at the cell body and not every change in intracellular [Ca<sup>2+</sup>] will necessarily result from action potential firing. Regardless of the limitations, in vivo Ca<sup>2+</sup>-imaging provides a powerful tool to enhance our understanding of how the nociceptive system works and the power of genetics means that it will be ever more possible to express a GCaMP indicator in a discrete neuronal subset to selectively determine its contribution to nociception and how this changes in neuropathic pain.</p><p id="Par6">In addition to functional experiments, single-cell RNA-sequencing of sensory neurones has shown that neurones can be split into groups according to their transcriptome [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], research that builds on earlier whole DRG RNA-sequencing studies that investigated how neuronal expression profiles change in neuropathic pain [<xref ref-type="bibr" rid="CR27">27</xref>]. A significant advantage of single-cell RNA-sequencing is the unbiased nature of how data are produced. However, to harness the true power of single-cell RNA-sequencing, it should be conducted on sensory neurones of known anatomical innervation, i.e., through use of retrograde labelling techniques, because this technique has been used to show that neurones innervating different tissues have distinct properties. For example, NaV1.7 is expressed in NaV1.8-positive colonic neurones and yet mice lacking NaV1.7 in NaV1.8-positive neurones although having diminished somatic pain, experience normal visceral pain [<xref ref-type="bibr" rid="CR28">28</xref>]; articular neurones have smaller acid responses, but greater likelihood of responding to ATP than cutaneous neurones [<xref ref-type="bibr" rid="CR29">29</xref>], and of all 6 ASIC subunits, ASIC3 mediates acid-excitation of dural, corneal, and cardiac afferents, possibly contributing to the pain of headache, corneal pathologies, and cardiac ischaemia, respectively [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par7">In the near future, it is likely that retrograde tracing will be coupled with RNA-sequencing to identify the molecular fingerprint of distinct neuronal subsets innervating different tissues. With such information to hand, different proteins and/or neuronal subsets can be targeted using transgenic mouse techniques to determine their contribution to neuropathic pain and thus identify novel analgesic targets.</p></sec><sec id="Sec4"><title>Unlocking nociceptor circuitry</title><p id="Par8">Two further techniques recently utilised to further understanding of nociceptor function and circuitry are optogenetics and chemogenetics. Optogenetics involves inducing neuronal expression of light-activated membrane proteins whose activation can enable either depolarisation (e.g., channelrhodopsin-2, ChR2) or hyperpolarisation (e.g., halorhodopsin) to directly switch-on or switch-off neurones, respectively, as well as switching on of G protein-coupled receptor (GPCR) signalling cascades [<xref ref-type="bibr" rid="CR33">33</xref>]. By contrast, chemogenetics entails, among other strategies, designer receptors exclusively activated by designer drugs (DREADDs), which are modified GPCRs no longer activated by their endogenous ligand acetylcholine, but instead the biologically inert substance clozapine-<italic>N</italic>-oxide (CNO, although recent work suggests that clozapine rather than CNO is the receptor ligand [<xref ref-type="bibr" rid="CR34">34</xref>]); differently G protein-coupled DREADDs allow for activation (G<sub>s</sub> or G<sub>q</sub>) or inhibition (G<sub>i</sub>) of neuronal function [<xref ref-type="bibr" rid="CR35">35</xref>]. Using tissue-specific promoters, optogenetic and chemogenetic approaches can target distinct neuronal subsets. For example, plantar paw light stimulation in freely moving mice expressing ChR2 in NaV1.8-positive sensory neurones robustly produced nocifensive behaviours [<xref ref-type="bibr" rid="CR36">36</xref>]. Like optogenetics, chemogenetics provides the potential to control neuronal function. For example, administration of CNO to mice expressing a G<sub>i</sub>-coupled DREADD in sensory neurones known to play a role in heat sensation increased the latency for paw withdrawal from a hot stimulus [<xref ref-type="bibr" rid="CR37">37</xref>]. However, this study also raised concern about the use of DREADDs, because changes were observed in basal neuronal function, such as alterations in the amplitude of currents mediated by different NaV subunits. Therefore, results from DREADD studies hold great potential, but should be interpreted with caution and their future clinical use through gene therapy must control for certain risks. An alternative, but similar approach has recently been developed whereby viral transduction of an engineered chloride-channel sensitive to ivermectin (GluCl v2.0) was capable of long-term repeatable suppression of sensory neuron sensitivity and amelioration of neuropathic pain in rodents; the expression of GluCl v2.0 in human-induced pluripotent stem cell derived sensory neurones was also shown to cause their silencing in an ivermectin-dependent manner [<xref ref-type="bibr" rid="CR38">38</xref>]. Overall, the ability to selectively control the excitability of neuronal subpopulations using either chemo- or optogenetic tools offers an attractive way of treating neuropathic pain compared to orally taken medications, which result in the whole body being exposed to the drug. Although such manipulations are likely still some way off, clinical trials for using ChR2 to treat advanced retinitis pigmentosa are underway [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par9">Optogenetics and chemogenetics are also being used to further understanding about the circuitry of pain. In 1965, Melzack and Wall published the landmark paper <italic>Pain Mechanisms: a new theory</italic>, part of which suggested that input from low-threshold mechanoreceptors (LTMRs) inhibits nociceptor neurotransmission in the spinal cord [<xref ref-type="bibr" rid="CR40">40</xref>]. Optogenetics has shown that ChR2 activation in a subset of myelinated A-fibre nociceptors required for mechanonociception produces an exaggerated pain response, which was mitigated when ChR2 was simultaneously expressed in LTMRs [<xref ref-type="bibr" rid="CR41">41</xref>]. Co-activation of mechanonociceptors and LTMRs also resulted in fewer superficial dorsal horn neurones being activated compared to when mechanonociceptors were activated alone, which lends further support to Melzack and Wall&#x02019;s theory that LTMR activation inhibits nociception. Studies such as this demonstrate the power of optogenetics for unravelling nociceptor neuronal circuitry, and in the next few years, optogenetics will likely be applied to determining how nociceptor circuitry becomes altered in neuropathic pain, which may identify potentially novel routes of analgesia, as well as, perhaps, providing explanations for side effects associated with current interventions.</p></sec></sec><sec id="Sec5"><title>Clinical insights into neuropathic pain from pre-clinical research</title><p id="Par10">As described in the Introduction, neuropathic pain is common and chronic pain sufferers often receive inadequate pain relief from current medications. A 2015 meta-analysis of trials looking at pharmacological treatments for neuropathic pain identified that although there is strong recommendation for the use of certain drugs (e.g., gabapentin, pregabalin, serotonin/noradrenaline reuptake inhibitors, and tricyclic antidepressants), the effects are relatively modest: the number needed to treat (NNT) to produce a 50% reduction in pain for those drugs with strong recommendation for use ranges from 3.6 to 7.7, i.e., 4&#x02013;8 patients must be treated for one patient to experience at least 50% pain reduction when the placebo response is subtracted [<xref ref-type="bibr" rid="CR42">42</xref>]. In addition to pharmacological treatment, a variety of other interventions are available for neuropathic pain, including: physical and psychological therapies, spinal cord stimulation, surgery, and transcranial magnetic stimulation (TMS), but here, discussion will be focused on the potential for the development of novel pharmacotherapy resulting from enhanced understanding of the molecular basis of neuropathic pain.</p><sec id="Sec6"><title>Pre-clinical animal models</title><p id="Par11">A major problem with regard to studying and treating neuropathic pain is its highly variable aetiology, ranging from brain lesions to demyelinating diseases of the spinal cord, and peripheral neuropathy resulting from conditions such as diabetes mellitus or as a result of anti-cancer chemotherapy. Pre-clinically, most studies are conducted on rodents and involve direct nerve injury, often to the sciatic nerve, which, although bearing poor resemblance to the case history of most neuropathic pain patients, does enable disease processes to be investigated and many treatments used clinically are able to reverse the pain behaviours observed in these models [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition to surgical models, there are also animal models that more closely resemble human disease pathogenesis, e.g., diabetic neuropathy [<xref ref-type="bibr" rid="CR44">44</xref>] and certain chemotherapy treatments [<xref ref-type="bibr" rid="CR45">45</xref>]. However, there has been a long-standing problem in efficiently translating analgesics from animal models through to the clinic, either due to lack of efficacy or due to side effects [<xref ref-type="bibr" rid="CR46">46</xref>]. There are several potential reasons that have hindered translation of drugs, including: the highly varied aetiology of neuropathic pain in humans compared to the relatively restricted animal models, the in-bred (and thus genetically homogenous) animal subjects compared to the more genetically heterogeneous human population, and the difference in how pain assessed, i.e., most animal studies measure stimulus-evoked withdrawal behaviours, whereas neuropathic pain patients will often describe spontaneous pain. From the animal pain model perspective, it would, therefore, be advantageous to develop paradigms that measure changes in normal behaviour, e.g., suppression of burrowing can occur as a result of pain-induced changes in general well-being [<xref ref-type="bibr" rid="CR47">47</xref>], alongside measurements of evoked pain. At the same time, it is, perhaps, necessary to try and better identify groups of patients for which a potential novel therapy may be of benefit when recruiting for clinical trials. Recent multicentre clustering analysis of quantitative sensory testing parameters measured in patients with different aetiologies has identified three distinct patient subgroups (sensory loss, thermal hyperalgesia and mechanical hyperalgesia), which may be underpinned by distinct pathological mechanisms. Thus, this may help to stratify patients for clinical trials testing analgesics arising from animal models where the mechanism of action is often well understood [<xref ref-type="bibr" rid="CR48">48</xref>]. Subsequently, an algorithm has been developed to allocate patients to each subgroup, which should aid the stratification of patients both with regard to identifying appropriate patients for clinical trials and may enable easier identification of an individual patient&#x02019;s optimal treatment regime [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par12">Although animal models of neuropathic pain have their limitations and translation is currently far from perfect, such models have identified changes at all levels in the pain pathway in neuropathic pain, from alterations in sensory neurone protein expression to changes in spinal cord synaptic function and in the descending control of pain from the brain, some of which will now be discussed to shed light on potential future medications.</p></sec><sec id="Sec7"><title>Targeting action potential electrogenesis</title><p id="Par13">From a therapeutic point of view, cutting off pain signals within the primary afferent nociceptor might be predicted to have fewer side effects than targeting a process within the central nervous system. To validate this approach, injection of the local anaesthetic lidocaine, which blocks all NaV subunits, at painful foci in patients suffering from painful neuropathy greatly diminished allodynia, suggesting that ongoing nociceptor input drives neuropathic pain [<xref ref-type="bibr" rid="CR50">50</xref>]. What makes targeting of NaV subunits particularly appealing is that some neuropathic pain patients experience pain as a result of gain-of-function NaV mutations (for a review of these and other pain-related mutations, see [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]). The NaV1.7 subunit is commonly affected, mutations often causing a shift in the activation threshold (a smaller stimulus evokes pain) and/or slow inactivation (once activated the nerve fires for longer) [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. There are also NaV1.7 mutations that produce congenital insensitivity to pain [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], but are not associated with serious systemic side effects (likely due to NaV1.7 expression being largely restricted to the peripheral nervous system), which suggests that selective inhibition of NaV1.7 could result in pain relief without producing a plethora of neurological side effects. Transgenic mouse models where NaV1.7 has been deleted in different neuronal subsets have demonstrated its critical contribution to different forms of pain [<xref ref-type="bibr" rid="CR55">55</xref>], and recent work suggests that NaV1.7 activity also regulates endogenous opioid release, such that combining an NaV1.7 inhibitor with an opioid may provide synergistic analgesia with fewer side effects [<xref ref-type="bibr" rid="CR56">56</xref>]. A recent Phase 2a trial in trigeminal neuralgia patients demonstrated that the selective NaV1.7 inhibitor BIIB074 produced fewer treatment failures than placebo and a better improvement in the daily pain score than placebo during the double-blind phase [<xref ref-type="bibr" rid="CR57">57</xref>], results that are encouraging, but clearly larger trials are needed, especially those aimed at determining if BIIB074 is actually more efficacious and/or provides a lower side effect burden than the current first-line medications for trigeminal neuralgia, such as carbamazepine. Mutations in NaV1.8 can also underlie painful neuropathy in humans [<xref ref-type="bibr" rid="CR58">58</xref>] and transgenic mouse work has identified a critical role for NaV1.8 in acute cold pain [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], as well as cold allodynia in some neuropathic pain models [<xref ref-type="bibr" rid="CR61">61</xref>]. Finally, mutations in NaV1.9 can cause both congenital insensitivity to pain [<xref ref-type="bibr" rid="CR62">62</xref>] and painful neuropathy [<xref ref-type="bibr" rid="CR63">63</xref>] in humans, and transgenic mouse work supports a role for NaV1.9 in inflammatory [<xref ref-type="bibr" rid="CR64">64</xref>], neuropathic [<xref ref-type="bibr" rid="CR61">61</xref>], and visceral pain [<xref ref-type="bibr" rid="CR65">65</xref>], suggesting that like NaV1.7 and NaV1.8, NaV1.9 could be targeted to produce pain relief in certain neuropathic pain conditions. However, a key challenge for targeting any NaV subunit is to develop high enough subunit specificity to avoid off-target effects (e.g., inhibition of cardiac NaV1.5); a future possibility may be target modulators of NaV alpha subunits, rather than the alpha subunits themselves, for example beta subunits that modulate alpha subunit biophysical activity [<xref ref-type="bibr" rid="CR66">66</xref>]. By contrast with inhibiting NaV subunits, there are numerous voltage-gated potassium channels (Kv) involved in sensory neurone action potential generation, which could also be targeted by a channel opener drug to relieve neuropathic pain [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. One promising example is retigabine, which is a Kv7 opener used as an anticonvulsant, but has also been shown to attenuate neuropathic pain in rodents [<xref ref-type="bibr" rid="CR69">69</xref>]. However, a recent clinical trial looking at the effects of retigabine for treating postherpetic neuralgia, failed to find any difference compared to placebo in the primary endpoint of a change from baseline in the average pain score in the last 7&#x000a0;days of the maintenance phase [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par14">In terms of action potential transmission, hyperpolarisation activated, cyclic nucleotide-gated ion channel (HCN) subunits are activated during&#x000a0;the repolarization&#x000a0;phase of action potential firing and are critical in returning a neurone to its resting membrane potential. The HCN2 subunit is predominantly expressed in sensory neurones and can be modulated by cyclic adenosine monophosphate (cAMP) to fire at more depolarised potentials, which induces trains of action potential firing [<xref ref-type="bibr" rid="CR71">71</xref>]. The modulation of HCN2 by cAMP may well be important, because mice lacking HCN2 in a subset of sensory neurones fail to develop neuropathic pain [<xref ref-type="bibr" rid="CR72">72</xref>] and ivabradine, which is a non-selective, peripherally restricted anti-anginal drug, reverses neuropathic pain in mice as effectively as gabapentin [<xref ref-type="bibr" rid="CR73">73</xref>]. To date, however, no clinical trials have been published on the use of ivabradine for neuropathic pain. A potential complication lies in ivabradine&#x02019;s non-selectivity, such that its blockade of cardiac HCN4 produces bradycardia at similar doses to those producing a relief from neuropathic pain [<xref ref-type="bibr" rid="CR73">73</xref>], and thus, the search is on for a selective HCN2 inhibitor.</p></sec><sec id="Sec8"><title>Targeting transduction</title><p id="Par15">As an alternative to reducing action potential firing through NaV or HCN blockade, the nociceptor transduction process itself could be disrupted. Mechanical hyperalgesia/allodynia is common features of neuropathic pain [<xref ref-type="bibr" rid="CR48">48</xref>] and, in recent years, progress has been made in understanding how sensory neurones are activated by mechanical stimuli [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. The mechanically activated ion channel Piezo2 is necessary for normal touch sensitivity, but it is not involved in detecting noxious mechanical forces or in inflammatory mechanical hyperalgesia in mice [<xref ref-type="bibr" rid="CR76">76</xref>]; it is, however, sensitised by signalling pathways associated with neuropathic pain [<xref ref-type="bibr" rid="CR77">77</xref>]. Although Piezo ion channels are intrinsically mechanosensitive [<xref ref-type="bibr" rid="CR78">78</xref>], the activation threshold for Piezo2 is reduced by stomatin-like protein 3 (STOML3) [<xref ref-type="bibr" rid="CR79">79</xref>]. Studies in mice have shown that neuronal mechanosensitivity is lowered in neurones from mice lacking STOML3 [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>], that neuronal STOML3 expression is elevated in mouse neuropathic pain models [<xref ref-type="bibr" rid="CR81">81</xref>] and mice lacking STOML3 show greatly reduced mechanical allodynia in neuropathic pain models [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>], i.e., targeting STOML3 may act to relieve the mechanical allodynia associated with neuropathic pain. The modulation of cellular mechanosensitivity by STOML3 is dependent upon its ability to form oligomers [<xref ref-type="bibr" rid="CR79">79</xref>] and recent research identified two compounds that prevent oligomerisation and reverse neuropathic pain in mice [<xref ref-type="bibr" rid="CR81">81</xref>], which highlights the tractability of such protein&#x02013;protein interactions for pharmacotherapy. Compounds disrupting STOML3 oligomerisation prevented mechanical allodynia not only in nerve injury models, but also in a model of diabetic neuropathy [<xref ref-type="bibr" rid="CR81">81</xref>], which raises hopes of possibly developing this therapeutic avenue for treating patients with diabetic neuropathy who experience a range of disturbances in mechanosensitivity, including dynamic mechanical allodynia [<xref ref-type="bibr" rid="CR82">82</xref>].</p></sec><sec id="Sec9"><title>Interfering with central processing</title><p id="Par16">In addition to targeting the primary afferent sensory neurone itself, an alternative is to target spinal cord neurotransmission between first- and second-order neurones. The CaV2.2 inhibitor ziconotide is used in the treatment of neuropathic pain and acts by blocking presynaptic CaV subunits to inhibit neurotransmission [<xref ref-type="bibr" rid="CR83">83</xref>]. A major drawback is that to prevent systemic side effects, ziconotide must be administered intrathecally, which requires the implantation of a minipump. By determining the spinal cord pathology in neuropathic pain, it is hoped that more targeted therapies could be developed. Using rodent neuropathic pain models, it has been shown that the expression of glutamic acid decarboxylase (GAD, which synthesises the inhibitory neurotransmitter &#x003b3;-aminobutyric acid, GABA) decreases following nerve injury [<xref ref-type="bibr" rid="CR84">84</xref>]. Furthermore, some [<xref ref-type="bibr" rid="CR85">85</xref>] but not all [<xref ref-type="bibr" rid="CR86">86</xref>] studies have found that the number of GABAergic neurones decreases in neuropathic pain. With lowered GABAergic tone likely contributing to neuropathic pain it is thought that therapies which normalise GABAergic neurotransmission may be beneficial. Indeed, in rodents, positive modulation of &#x003b1;<sub>2</sub> and/or &#x003b1;<sub>3</sub> subunit containing GABA<sub>A</sub> receptors reverses neuropathic pain [<xref ref-type="bibr" rid="CR87">87</xref>]. However, a potential limitation of drugs that target GABA<sub>A</sub> receptors is that they are widely expressed in the brain and thus may potentially produce unwanted side effects. To bypass this problem, recent work has shown that progenitors of GABAergic neurones can be transplanted into the spinal cord and integrate with the spinal cord circuitry to reverse nerve injury-induced and chemotherapy-induced neuropathic pain [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]; unlike systemic injection of GABA receptor modulators that may modulate off-target GABAergic function, no migration of the progenitors outside of the segment into which injections were made was observed, thus diminishing the potential for side effects. Finally, over the last 15&#x000a0;years, research from several groups has also demonstrated a key interaction between spinal cord microglia and GABAergic function in neuropathic pain. Following the induction of neuropathic pain in rodents, spinal cord microglia are activated [<xref ref-type="bibr" rid="CR90">90</xref>], and release brain-derived neurotrophic factor (BDNF) [<xref ref-type="bibr" rid="CR91">91</xref>], which decreases neuronal K<sup>+</sup>/Cl<sup>&#x02212;</sup> co-transporter 2 (KCC2) expression [<xref ref-type="bibr" rid="CR92">92</xref>]. Lowered KCC2 expression shifts the Cl<sup>&#x02212;</sup> concentration gradient, such that GABA<sub>A</sub> receptor activation no longer causes inhibition, but can actually cause excitation of projection neurones [<xref ref-type="bibr" rid="CR93">93</xref>]. An experimental compound has been identified that increases KCC2 surface expression, which normalises the intracellular Cl<sup>&#x02212;</sup> concentration, reverses mechanical allodynia in rats, and validates the prospect of targeting KCC2 to produce analgesia in neuropathic pain [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par17">As well as diminished central inhibitory function in neuropathic pain, central circuits become hyperexcitable and understanding the mechanisms involved offers further potential for identifying new druggable targets for treating neuropathic pain [<xref ref-type="bibr" rid="CR95">95</xref>]. One key process is long-term potentiation (LTP), an increase in synaptic strength following an elevated level of primary afferent input, which involves the glutamate <italic>N</italic>-methyl-D-aspartate (NMDA) receptor [<xref ref-type="bibr" rid="CR96">96</xref>]. However, NMDA receptors are present throughout the nervous system and the non-analgesic effects of the recreational drug ketamine that blocks NMDA receptor activity (e.g., hallucinations and memory impairment), which demonstrate that systemic blockade of NMDA receptors is not a feasible route for standard neuropathic pain treatment, as such a peripherally restricted approach is likely to be necessary.</p></sec></sec><sec id="Sec10"><title>Conclusions</title><p id="Par18">In summary, neuropathic pain is a common condition with highly variably aetiology and for which the current treatments are often inefficacious and/or produce severe side effects. Pre-clinical research, largely using rodent models, but recently driven by human genetics, is focused on understanding how the nervous system changes during neuropathic pain in an effort to identify novel targets for analgesia and to validate their druggability. Rapid advances in technology have resulted in the development of many novel tools, such as chemo- and optogenetics, which will be applied to make further inroads into the pathogenesis of neuropathic pain using animal models, as well as having the potential to be developed clinically as highlighted by the current clinical trials with ChR2 in advanced retinitis pigmentosa. Finally, work in recent years has already identified several novel drug targets, such as NaV1.7, HCN2, STOML3, and KCC2, and future clinical trials will determine their true potential as targets for novel analgesics.</p></sec></body><back><ack><title>Acknowledgements</title><p>I acknowledge funding from Arthritis Research UK (Grant Reference 20930) and the Rosetrees Trust (Grant Reference A1296), which support pain research in my group. I also acknowledge Drs. Gerard Callejo and James Hockley, as well as Reviewers, for expert critique of the manuscript.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflicts of interest</title><p id="Par19">I have no conflict of interest.</p></sec><sec id="d29e706"><title>Ethical statement</title><p>No human or animal research was conducted in writing this review.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">IASP Taxonomy. <ext-link ext-link-type="uri" xlink:href="http://www.iasp-pain.org/Taxonomy">http://www.iasp-pain.org/Taxonomy</ext-link>. Accessed 15 May 2017</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>ES</given-names></name><name><surname>Lewin</surname><given-names>GR</given-names></name></person-group><article-title>Nociceptors: a phylogenetic view</article-title><source>J Comp Physiol A</source><year>2009</year><volume>195</volume><fpage>1089</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1007/s00359-009-0482-z</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sneddon</surname><given-names>LU</given-names></name></person-group><article-title>Pain in aquatic animals</article-title><source>J Exp Biol</source><year>2015</year><volume>218</volume><fpage>967</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1242/jeb.088823</pub-id><?supplied-pmid 25833131?><pub-id pub-id-type="pmid">25833131</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>RJ</given-names></name><name><surname>Walters</surname><given-names>ET</given-names></name></person-group><article-title>Nociceptive behavior and physiology of molluscs: animal welfare implications</article-title><source>ILAR J</source><year>2011</year><volume>52</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1093/ilar.52.2.185</pub-id><?supplied-pmid 21709311?><pub-id pub-id-type="pmid">21709311</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>AE</given-names></name><name><surname>Patapoutian</surname><given-names>A</given-names></name></person-group><article-title>Nociceptors: the sensors of the pain pathway</article-title><source>J Clin Investig</source><year>2010</year><volume>120</volume><fpage>3760</fpage><lpage>3772</lpage><pub-id pub-id-type="doi">10.1172/JCI42843</pub-id><?supplied-pmid 21041958?><pub-id pub-id-type="pmid">21041958</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuner</surname><given-names>R</given-names></name><name><surname>Flor</surname><given-names>H</given-names></name></person-group><article-title>Structural plasticity and reorganisation in chronic pain</article-title><source>Nat Rev Neurosci</source><year>2016</year><volume>18</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.162</pub-id><?supplied-pmid 27974843?><pub-id pub-id-type="pmid">27974843</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>AJ</given-names></name></person-group><article-title>Neuronal circuitry for pain processing in the dorsal horn</article-title><source>Nat Rev Neurosci</source><year>2010</year><volume>11</volume><fpage>823</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1038/nrn2947</pub-id><?supplied-pmid 21068766?><pub-id pub-id-type="pmid">21068766</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>MS</given-names></name><name><surname>Gebhart</surname><given-names>GF</given-names></name></person-group><article-title>Nociceptor sensitization in pain pathogenesis</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><fpage>1248</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1038/nm.2235</pub-id><?supplied-pmid 20948530?><pub-id pub-id-type="pmid">20948530</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basbaum</surname><given-names>AI</given-names></name><name><surname>Bautista</surname><given-names>DM</given-names></name><name><surname>Scherrer</surname><given-names>G</given-names></name><name><surname>Julius</surname><given-names>D</given-names></name></person-group><article-title>Cellular and molecular mechanisms of pain</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>267</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.09.028</pub-id><?supplied-pmid 19837031?><pub-id pub-id-type="pmid">19837031</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewin</surname><given-names>GR</given-names></name><name><surname>Lechner</surname><given-names>SG</given-names></name><name><surname>Smith</surname><given-names>ESJ</given-names></name></person-group><article-title>Nerve growth factor and nociception: from experimental embryology to new analgesic therapy</article-title><source>Handb Exp Pharmacol</source><year>2014</year><volume>220</volume><fpage>251</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-45106-5_10</pub-id><?supplied-pmid 24668476?><pub-id pub-id-type="pmid">24668476</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dib-Hajj</surname><given-names>SD</given-names></name><name><surname>Waxman</surname><given-names>SG</given-names></name></person-group><article-title>Translational pain research: Lessons from genetics and genomics</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>249sr4</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007017</pub-id><?supplied-pmid 25122641?><pub-id pub-id-type="pmid">25122641</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>DLH</given-names></name><name><surname>Woods</surname><given-names>CG</given-names></name></person-group><article-title>Painful and painless channelopathies</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>587</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70024-9</pub-id><?supplied-pmid 24813307?><pub-id pub-id-type="pmid">24813307</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>C</given-names></name></person-group><article-title>Exploring pain pathophysiology in patients</article-title><source>Science</source><year>2016</year><volume>354</volume><fpage>588</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1126/science.aaf8935</pub-id><?supplied-pmid 27811270?><pub-id pub-id-type="pmid">27811270</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabr&#x000f2;</surname><given-names>A</given-names></name><name><surname>Caterino</surname><given-names>AL</given-names></name><name><surname>Elefante</surname><given-names>E</given-names></name><etal/></person-group><article-title>One year in review 2016: novelties in the treatment of rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2016</year><volume>34</volume><fpage>357</fpage><lpage>372</lpage><?supplied-pmid 27268779?><pub-id pub-id-type="pmid">27268779</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colloca</surname><given-names>L</given-names></name><name><surname>Ludman</surname><given-names>T</given-names></name><name><surname>Bouhassira</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neuropathic pain</article-title><source>Nat Rev Dis Primers</source><year>2017</year><volume>3</volume><fpage>17002</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.2</pub-id><?supplied-pmid 28205574?><pub-id pub-id-type="pmid">28205574</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Zempsky</surname><given-names>W</given-names></name></person-group><article-title>Pharmacologic treatment of pain</article-title><source>Semin Pediatr Neurol</source><year>2016</year><volume>23</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.spen.2016.10.004</pub-id><?supplied-pmid 27989328?><pub-id pub-id-type="pmid">27989328</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahin</surname><given-names>RL</given-names></name></person-group><article-title>Estimates of pain prevalence and severity in adults: United States, 2012</article-title><source>J Pain</source><year>2015</year><volume>16</volume><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2015.05.002</pub-id><?supplied-pmid 26028573?><pub-id pub-id-type="pmid">26028573</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breivik</surname><given-names>H</given-names></name><name><surname>Collett</surname><given-names>B</given-names></name><name><surname>Ventafridda</surname><given-names>V</given-names></name><etal/></person-group><article-title>Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment</article-title><source>Eur J Pain</source><year>2006</year><volume>10</volume><fpage>287</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2005.06.009</pub-id><?supplied-pmid 16095934?><pub-id pub-id-type="pmid">16095934</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riskowski</surname><given-names>JL</given-names></name></person-group><article-title>Associations of socioeconomic position and pain prevalence in the United States: findings from the National Health and Nutrition Examination Survey</article-title><source>Pain Med</source><year>2014</year><volume>15</volume><fpage>1508</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1111/pme.12528</pub-id><?supplied-pmid 25138172?><pub-id pub-id-type="pmid">25138172</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hecke</surname><given-names>O</given-names></name><name><surname>Austin</surname><given-names>SK</given-names></name><name><surname>Khan</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Neuropathic pain in the general population: a systematic review of epidemiological studies</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>654</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.11.013</pub-id><?supplied-pmid 24291734?><pub-id pub-id-type="pmid">24291734</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichling</surname><given-names>DB</given-names></name><name><surname>Green</surname><given-names>PG</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name></person-group><article-title>The fundamental unit of pain is the cell</article-title><source>Pain</source><year>2013</year><volume>154</volume><fpage>S2</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.05.037</pub-id><?supplied-pmid 23711480?><pub-id pub-id-type="pmid">23711480</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>EC</given-names></name><name><surname>Luiz</surname><given-names>AP</given-names></name><name><surname>Sikandar</surname><given-names>S</given-names></name><etal/></person-group><article-title>In vivo characterization of distinct modality-specific subsets of somatosensory neurons using GCaMP</article-title><source>Sci Adv</source><year>2016</year><volume>2</volume><fpage>e1600990</fpage><pub-id pub-id-type="doi">10.1126/sciadv.1600990</pub-id><?supplied-pmid 27847865?><pub-id pub-id-type="pmid">27847865</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-Edwards</surname><given-names>KM</given-names></name><name><surname>DeBerry</surname><given-names>JJ</given-names></name><name><surname>Saloman</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Profound alteration in cutaneous primary afferent activity produced by inflammatory mediators</article-title><source>eLife</source><year>2016</year><?supplied-pmid 27805567?><pub-id pub-id-type="pmid">27805567</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><etal/></person-group><article-title>Coupled activation of primary sensory neurons contributes to chronic pain</article-title><source>Neuron</source><year>2016</year><volume>91</volume><fpage>1085</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.07.044</pub-id><?supplied-pmid 27568517?><pub-id pub-id-type="pmid">27568517</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C-L</given-names></name><name><surname>Li</surname><given-names>K-C</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity</article-title><source>Cell Res</source><year>2016</year><volume>26</volume><fpage>83</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.149</pub-id><?supplied-pmid 26691752?><pub-id pub-id-type="pmid">26691752</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usoskin</surname><given-names>D</given-names></name><name><surname>Furlan</surname><given-names>A</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing</article-title><source>Nat Neurosci</source><year>2014</year><volume>18</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nn.3881</pub-id><?supplied-pmid 25420068?><pub-id pub-id-type="pmid">25420068</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>JR</given-names></name><name><surname>Antunes-Martins</surname><given-names>A</given-names></name><name><surname>Calvo</surname><given-names>M</given-names></name><etal/></person-group><article-title>A comparison of RNA-seq and exon arrays for whole genome transcription profiling of the L5 spinal nerve transection model of neuropathic pain in the rat</article-title><source>Mol Pain</source><year>2014</year><volume>10</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1744-8069-10-7</pub-id><?supplied-pmid 24472155?><pub-id pub-id-type="pmid">24472155</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockley</surname><given-names>JRF</given-names></name><name><surname>Gonz&#x000e1;lez-Cano</surname><given-names>R</given-names></name><name><surname>McMurray</surname><given-names>S</given-names></name><etal/></person-group><article-title>Visceral and somatic pain modalities reveal Na<sub>V</sub> 1.7-independent visceral nociceptive pathways</article-title><source>J Physiol</source><year>2017</year><volume>595</volume><fpage>2661</fpage><lpage>2679</lpage><pub-id pub-id-type="doi">10.1113/JP272837</pub-id><?supplied-pmid 28105664?><pub-id pub-id-type="pmid">28105664</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>Serra I</given-names></name><name><surname>Husson</surname><given-names>Z</given-names></name><name><surname>Bartlett</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>ESJ</given-names></name></person-group><article-title>Characterization of cutaneous and articular sensory neurons</article-title><source>Mol Pain</source><year>2016</year><?supplied-pmid 27317579?><pub-id pub-id-type="pmid">27317579</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Bischoff</surname><given-names>C</given-names></name><etal/></person-group><article-title>pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators</article-title><source>Headache</source><year>2013</year><volume>53</volume><fpage>1250</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1111/head.12152</pub-id><?supplied-pmid 23808707?><pub-id pub-id-type="pmid">23808707</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Immke</surname><given-names>DC</given-names></name><name><surname>McCleskey</surname><given-names>EW</given-names></name></person-group><article-title>Lactate enhances the acid-sensing Na<sup>+</sup> channel on ischemia-sensing neurons</article-title><source>Nat Neurosci</source><year>2001</year><volume>4</volume><fpage>869</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1038/nn0901-869</pub-id><?supplied-pmid 11528414?><pub-id pub-id-type="pmid">11528414</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callejo</surname><given-names>G</given-names></name><name><surname>Castellanos</surname><given-names>A</given-names></name><name><surname>Castany</surname><given-names>M</given-names></name><etal/></person-group><article-title>Acid-sensing ion channels detect moderate acidifications to induce ocular pain</article-title><source>Pain</source><year>2015</year><volume>156</volume><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1097/01.j.pain.0000460335.49525.17</pub-id><?supplied-pmid 25687542?><pub-id pub-id-type="pmid">25687542</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czapi&#x00144;ski</surname><given-names>J</given-names></name><name><surname>Kie&#x00142;bus</surname><given-names>M</given-names></name><name><surname>Ka&#x00142;afut</surname><given-names>J</given-names></name><etal/></person-group><article-title>How to train a cell&#x02014;cutting-edge molecular tools</article-title><source>Front Chem</source><year>2017</year><?supplied-pmid 28344971?><pub-id pub-id-type="pmid">28344971</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>JL</given-names></name><name><surname>Bonaventura</surname><given-names>J</given-names></name><name><surname>Lesniak</surname><given-names>W</given-names></name><etal/></person-group><article-title>Chemogenetics revealed: DREADD occupancy and activation via converted clozapine</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1126/science.aan2475</pub-id><?supplied-pmid 28774929?><pub-id pub-id-type="pmid">28774929</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><article-title>DREADDs for neuroscientists</article-title><source>Neuron</source><year>2016</year><volume>89</volume><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.01.040</pub-id><?supplied-pmid 26889809?><pub-id pub-id-type="pmid">26889809</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daou</surname><given-names>I</given-names></name><name><surname>Tuttle</surname><given-names>AH</given-names></name><name><surname>Longo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Remote optogenetic activation and sensitization of pain pathways in freely moving mice</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>18631</fpage><lpage>18640</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2424-13.2013</pub-id><?supplied-pmid 24259584?><pub-id pub-id-type="pmid">24259584</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saloman</surname><given-names>JL</given-names></name><name><surname>Scheff</surname><given-names>NN</given-names></name><name><surname>Snyder</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Gi-DREADD expression in peripheral nerves produces ligand-dependent analgesia, as well as ligand-independent functional changes in sensory neurons</article-title><source>J Neurosci</source><year>2016</year><volume>36</volume><fpage>10769</fpage><lpage>10781</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3480-15.2016</pub-id><?supplied-pmid 27798132?><pub-id pub-id-type="pmid">27798132</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>GA</given-names></name><name><surname>Middleton</surname><given-names>SJ</given-names></name><name><surname>Clark</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Using an engineered glutamate-gated chloride channel to silence sensory neurons and treat neuropathic pain at the source</article-title><source>Brain</source><year>2017</year><?supplied-pmid 28969375?><pub-id pub-id-type="pmid">28969375</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">RST-001 phase I/II trial for advanced retinitis pigmentosa. Allergan (2015). <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02556736">https://clinicaltrials.gov/ct2/show/NCT02556736</ext-link></mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melzack</surname><given-names>R</given-names></name><name><surname>Wall</surname><given-names>PD</given-names></name></person-group><article-title>Pain mechanisms: a new theory</article-title><source>Science</source><year>1965</year><volume>150</volume><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1126/science.150.3699.971</pub-id><?supplied-pmid 5320816?><pub-id pub-id-type="pmid">5320816</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcourt</surname><given-names>A</given-names></name><name><surname>Gorham</surname><given-names>L</given-names></name><name><surname>Dhandapani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Touch receptor-derived sensory information alleviates acute pain signaling and fine-tunes nociceptive reflex coordination</article-title><source>Neuron</source><year>2017</year><volume>93</volume><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.11.027</pub-id><?supplied-pmid 27989460?><pub-id pub-id-type="pmid">27989460</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><name><surname>Haroutounian</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</article-title><source>Lancet Neurol</source><year>2015</year><volume>14</volume><fpage>162</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70251-0</pub-id><?supplied-pmid 25575710?><pub-id pub-id-type="pmid">25575710</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burma</surname><given-names>NE</given-names></name><name><surname>Leduc-Pessah</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>CY</given-names></name><name><surname>Trang</surname><given-names>T</given-names></name></person-group><article-title>Animal models of chronic pain: advances and challenges for clinical translation: animal models of chronic pain</article-title><source>J Neurosci Res</source><year>2017</year><volume>95</volume><fpage>1242</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1002/jnr.23768</pub-id><?supplied-pmid 27376591?><pub-id pub-id-type="pmid">27376591</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name></person-group><article-title>Animal models of diabetic neuropathic pain</article-title><source>Exp Clin Endocrinol Diabetes</source><year>2014</year><volume>122</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1055/s-0033-1363234</pub-id><?supplied-pmid 24554509?><pub-id pub-id-type="pmid">24554509</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hama</surname><given-names>A</given-names></name><name><surname>Takamatsu</surname><given-names>H</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neuropathic pain and rodent models</article-title><source>CNS Neurol Disord Drug Targets</source><year>2016</year><volume>15</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.2174/1871527315666151110125325</pub-id><?supplied-pmid 26553161?><pub-id pub-id-type="pmid">26553161</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>Current challenges in translational pain research</article-title><source>Trends Pharmacol Sci</source><year>2012</year><volume>33</volume><fpage>568</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2012.08.001</pub-id><?supplied-pmid 22959652?><pub-id pub-id-type="pmid">22959652</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodarski</surname><given-names>R</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Ultenius</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cross-centre replication of suppressed burrowing behaviour as an ethologically relevant pain outcome measure in the rat: a prospective multicentre study</article-title><source>Pain</source><year>2016</year><volume>157</volume><fpage>2350</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000657</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><etal/></person-group><article-title>Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles</article-title><source>Pain</source><year>2017</year><volume>158</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000753</pub-id><?supplied-pmid 27893485?><pub-id pub-id-type="pmid">27893485</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollert</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><etal/></person-group><article-title>Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations</article-title><source>Pain</source><year>2017</year><volume>158</volume><fpage>1446</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000935</pub-id><?supplied-pmid 28595241?><pub-id pub-id-type="pmid">28595241</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracely</surname><given-names>RH</given-names></name><name><surname>Lynch</surname><given-names>SA</given-names></name><name><surname>Bennett</surname><given-names>GJ</given-names></name></person-group><article-title>Painful neuropathy: altered central processing maintained dynamically by peripheral input</article-title><source>Pain</source><year>1992</year><volume>51</volume><fpage>175</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(92)90259-E</pub-id><?supplied-pmid 1484715?><pub-id pub-id-type="pmid">1484715</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummins</surname><given-names>TR</given-names></name><name><surname>Dib-Hajj</surname><given-names>SD</given-names></name><name><surname>Waxman</surname><given-names>SG</given-names></name></person-group><article-title>Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>8232</fpage><lpage>8236</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2695-04.2004</pub-id><?supplied-pmid 15385606?><pub-id pub-id-type="pmid">15385606</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fertleman</surname><given-names>CR</given-names></name><name><surname>Baker</surname><given-names>MD</given-names></name><name><surname>Parker</surname><given-names>KA</given-names></name><etal/></person-group><article-title>SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes</article-title><source>Neuron</source><year>2006</year><volume>52</volume><fpage>767</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.006</pub-id><?supplied-pmid 17145499?><pub-id pub-id-type="pmid">17145499</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JJ</given-names></name><name><surname>Reimann</surname><given-names>F</given-names></name><name><surname>Nicholas</surname><given-names>AK</given-names></name><etal/></person-group><article-title>An SCN9A channelopathy causes congenital inability to experience pain</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>894</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1038/nature05413</pub-id><?supplied-pmid 17167479?><pub-id pub-id-type="pmid">17167479</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>EC</given-names></name><name><surname>Habib</surname><given-names>AM</given-names></name><name><surname>Cox</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><fpage>7674</fpage><lpage>7681</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3935-14.2015</pub-id><?supplied-pmid 25995458?><pub-id pub-id-type="pmid">25995458</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minett</surname><given-names>MS</given-names></name><name><surname>Nassar</surname><given-names>MA</given-names></name><name><surname>Clark</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons</article-title><source>Nat Commun</source><year>2012</year><volume>3</volume><fpage>791</fpage><pub-id pub-id-type="doi">10.1038/ncomms1795</pub-id><?supplied-pmid 22531176?><pub-id pub-id-type="pmid">22531176</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minett</surname><given-names>MS</given-names></name><name><surname>Pereira</surname><given-names>V</given-names></name><name><surname>Sikandar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8967</fpage><pub-id pub-id-type="doi">10.1038/ncomms9967</pub-id><?supplied-pmid 26634308?><pub-id pub-id-type="pmid">26634308</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakrzewska</surname><given-names>JM</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Morisset</surname><given-names>V</given-names></name><etal/></person-group><article-title>Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial</article-title><source>Lancet Neurol</source><year>2017</year><volume>16</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30005-4</pub-id><?supplied-pmid 28216232?><pub-id pub-id-type="pmid">28216232</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>CG</given-names></name><name><surname>Lauria</surname><given-names>G</given-names></name><name><surname>Merkies</surname><given-names>ISJ</given-names></name><etal/></person-group><article-title>Gain-of-function Nav1.8 mutations in painful neuropathy</article-title><source>Proc Natl Acad Sci</source><year>2012</year><volume>109</volume><fpage>19444</fpage><lpage>19449</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216080109</pub-id><?supplied-pmid 23115331?><pub-id pub-id-type="pmid">23115331</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>K</given-names></name><name><surname>Leffler</surname><given-names>A</given-names></name><name><surname>Babes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>856</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1038/nature05880</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamsen</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Asante</surname><given-names>CO</given-names></name><etal/></person-group><article-title>The cell and molecular basis of mechanical, cold, and inflammatory pain</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1126/science.1156916</pub-id><?supplied-pmid 18669863?><pub-id pub-id-type="pmid">18669863</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minett</surname><given-names>MS</given-names></name><name><surname>Falk</surname><given-names>S</given-names></name><name><surname>Santana-Varela</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pain without nociceptors? Nav1.7-independent pain mechanisms</article-title><source>Cell Rep</source><year>2014</year><volume>6</volume><fpage>301</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.12.033</pub-id><?supplied-pmid 24440715?><pub-id pub-id-type="pmid">24440715</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leipold</surname><given-names>E</given-names></name><name><surname>Liebmann</surname><given-names>L</given-names></name><name><surname>Korenke</surname><given-names>GC</given-names></name><etal/></person-group><article-title>A de novo gain-of-function mutation in SCN11A causes loss of pain perception</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>1399</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1038/ng.2767</pub-id><?supplied-pmid 24036948?><pub-id pub-id-type="pmid">24036948</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Estacion</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>1627</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1093/brain/awu079</pub-id><?supplied-pmid 24776970?><pub-id pub-id-type="pmid">24776970</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priest</surname><given-names>BT</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name><name><surname>Lindia</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>9382</fpage><lpage>9387</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501549102</pub-id><?supplied-pmid 15964986?><pub-id pub-id-type="pmid">15964986</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockley</surname><given-names>JRF</given-names></name><name><surname>Boundouki</surname><given-names>G</given-names></name><name><surname>Cibert-Goton</surname><given-names>V</given-names></name><etal/></person-group><article-title>Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease-derived stimuli</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>1962</fpage><lpage>1975</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.06.015</pub-id><?supplied-pmid 24972070?><pub-id pub-id-type="pmid">24972070</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namadurai</surname><given-names>S</given-names></name><name><surname>Yereddi</surname><given-names>NR</given-names></name><name><surname>Cusdin</surname><given-names>FS</given-names></name><etal/></person-group><article-title>A new look at sodium channel subunits</article-title><source>Open Biol</source><year>2015</year><volume>5</volume><fpage>140192</fpage><pub-id pub-id-type="doi">10.1098/rsob.140192</pub-id><?supplied-pmid 25567098?><pub-id pub-id-type="pmid">25567098</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busserolles</surname><given-names>J</given-names></name><name><surname>Tsantoulas</surname><given-names>C</given-names></name><name><surname>Eschalier</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez Garc&#x000ed;a</surname><given-names>JA</given-names></name></person-group><article-title>Potassium channels in neuropathic pain: advances, challenges, and emerging ideas</article-title><source>Pain</source><year>2016</year><volume>157</volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>S14</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000368</pub-id><?supplied-pmid 26785158?><pub-id pub-id-type="pmid">26785158</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Jaffe</surname><given-names>D</given-names></name><etal/></person-group><article-title>M-type K(+) channels in peripheral nociceptive pathways</article-title><source>Br J Pharmacol</source><year>2017</year></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn-Munro</surname><given-names>G</given-names></name><name><surname>Jensen</surname><given-names>BS</given-names></name></person-group><article-title>The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain</article-title><source>Eur J Pharmacol</source><year>2003</year><volume>460</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(02)02924-2</pub-id><?supplied-pmid 12559370?><pub-id pub-id-type="pmid">12559370</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Valeant Pharmaceuticals International, Inc (2011) Safety/efficacy study of retigabine vs. placebo in post-herpetic neuralgia (PHN). In: ClinicalTrials.gov. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT00612105%3fsect%3dX756%26term%3dretigabine%26draw%3d3%26rank%3d19%23outcome1">https://clinicaltrials.gov/ct2/show/results/NCT00612105?sect=X756&#x00026;term=retigabine&#x00026;draw=3&#x00026;rank=19#outcome1</ext-link>. Accessed 7 Nov 2017</mixed-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momin</surname><given-names>A</given-names></name><name><surname>Cadiou</surname><given-names>H</given-names></name><name><surname>Mason</surname><given-names>A</given-names></name><name><surname>McNaughton</surname><given-names>PA</given-names></name></person-group><article-title>Role of the hyperpolarization-activated current Ih in somatosensory neurons</article-title><source>J Physiol</source><year>2008</year><volume>586</volume><fpage>5911</fpage><lpage>5929</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2008.163154</pub-id><?supplied-pmid 18936078?><pub-id pub-id-type="pmid">18936078</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>EC</given-names></name><name><surname>Young</surname><given-names>GT</given-names></name><name><surname>Berrocoso</surname><given-names>EM</given-names></name><etal/></person-group><article-title>HCN2 ion channels play a central role in inflammatory and neuropathic pain</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>1462</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1126/science.1206243</pub-id><?supplied-pmid 21903816?><pub-id pub-id-type="pmid">21903816</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>GT</given-names></name><name><surname>Emery</surname><given-names>EC</given-names></name><name><surname>Mooney</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>1708</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.05.021</pub-id><?supplied-pmid 24861581?><pub-id pub-id-type="pmid">24861581</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>K</given-names></name><name><surname>Moroni</surname><given-names>M</given-names></name><name><surname>Lewin</surname><given-names>GR</given-names></name></person-group><article-title>Sensory mechanotransduction at membrane&#x02013;matrix interfaces</article-title><source>Pflug Arch</source><year>2015</year><volume>467</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s00424-014-1563-6</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranade</surname><given-names>SS</given-names></name><name><surname>Syeda</surname><given-names>R</given-names></name><name><surname>Patapoutian</surname><given-names>A</given-names></name></person-group><article-title>Mechanically activated ion channels</article-title><source>Neuron</source><year>2015</year><volume>87</volume><fpage>1162</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.08.032</pub-id><?supplied-pmid 26402601?><pub-id pub-id-type="pmid">26402601</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranade</surname><given-names>SS</given-names></name><name><surname>Woo</surname><given-names>S-H</given-names></name><name><surname>Dubin</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Piezo2 is the major transducer of mechanical forces for touch sensation in mice</article-title><source>Nature</source><year>2014</year><volume>516</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/nature13980</pub-id><?supplied-pmid 25471886?><pub-id pub-id-type="pmid">25471886</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eijkelkamp</surname><given-names>N</given-names></name><name><surname>Linley</surname><given-names>JE</given-names></name><name><surname>Torres</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A role for Piezo2 in EPAC1-dependent mechanical allodynia</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>1682</fpage><pub-id pub-id-type="doi">10.1038/ncomms2673</pub-id><?supplied-pmid 23575686?><pub-id pub-id-type="pmid">23575686</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syeda</surname><given-names>R</given-names></name><name><surname>Florendo</surname><given-names>MN</given-names></name><name><surname>Cox</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Piezo1 channels are inherently mechanosensitive</article-title><source>Cell Rep</source><year>2016</year><volume>17</volume><fpage>1739</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.033</pub-id><?supplied-pmid 27829145?><pub-id pub-id-type="pmid">27829145</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>K</given-names></name><name><surname>Herget</surname><given-names>R</given-names></name><name><surname>Lapatsina</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tuning Piezo ion channels to detect molecular-scale movements relevant for fine touch</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3520</fpage><pub-id pub-id-type="doi">10.1038/ncomms4520</pub-id><?supplied-pmid 24662763?><pub-id pub-id-type="pmid">24662763</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Riethmacher</surname><given-names>D</given-names></name><etal/></person-group><article-title>A stomatin-domain protein essential for touch sensation in the mouse</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nature05394</pub-id><?supplied-pmid 17167420?><pub-id pub-id-type="pmid">17167420</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>C</given-names></name><name><surname>Pifferi</surname><given-names>S</given-names></name><name><surname>Picci</surname><given-names>C</given-names></name><etal/></person-group><article-title>Small-molecule inhibition of STOML3 oligomerization reverses pathological mechanical hypersensitivity</article-title><source>Nat Neurosci</source><year>2016</year><volume>20</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nn.4454</pub-id><?supplied-pmid 27941788?><pub-id pub-id-type="pmid">27941788</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Themistocleous</surname><given-names>AC</given-names></name><name><surname>Ramirez</surname><given-names>JD</given-names></name><name><surname>Shillo</surname><given-names>PR</given-names></name><etal/></person-group><article-title>The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy</article-title><source>Pain</source><year>2016</year><volume>157</volume><fpage>1132</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000491</pub-id><?supplied-pmid 27088890?><pub-id pub-id-type="pmid">27088890</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamponi</surname><given-names>GW</given-names></name></person-group><article-title>Targeting voltage-gated calcium channels in neurological and psychiatric diseases</article-title><source>Nat Rev Drug Discov</source><year>2015</year><volume>15</volume><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.5</pub-id><?supplied-pmid 26542451?><pub-id pub-id-type="pmid">26542451</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaton</surname><given-names>MJ</given-names></name><name><surname>Plunkett</surname><given-names>JA</given-names></name><name><surname>Karmally</surname><given-names>S</given-names></name><etal/></person-group><article-title>Changes in GAD- and GABA-immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors</article-title><source>J Chem Neuroanat</source><year>1998</year><volume>16</volume><fpage>57</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0891-0618(98)00062-3</pub-id><?supplied-pmid 9924973?><pub-id pub-id-type="pmid">9924973</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>J</given-names></name></person-group><article-title>Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>7317</fpage><lpage>7323</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1526-05.2005</pub-id><?supplied-pmid 16093381?><pub-id pub-id-type="pmid">16093381</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polg&#x000e1;r</surname><given-names>E</given-names></name><name><surname>Hughes</surname><given-names>DI</given-names></name><name><surname>Riddell</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain</article-title><source>Pain</source><year>2003</year><volume>104</volume><fpage>229</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(03)00011-3</pub-id><?supplied-pmid 12855333?><pub-id pub-id-type="pmid">12855333</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knabl</surname><given-names>J</given-names></name><name><surname>Witschi</surname><given-names>R</given-names></name><name><surname>H&#x000f6;sl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reversal of pathological pain through specific spinal GABAA receptor subtypes</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/nature06493</pub-id><?supplied-pmid 18202657?><pub-id pub-id-type="pmid">18202657</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000e1;z</surname><given-names>JM</given-names></name><name><surname>Sharif-Naeini</surname><given-names>R</given-names></name><name><surname>Vogt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Forebrain GABAergic neuron precursors integrate into adult spinal cord and reduce injury-induced neuropathic pain</article-title><source>Neuron</source><year>2012</year><volume>74</volume><fpage>663</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.02.033</pub-id><?supplied-pmid 22632725?><pub-id pub-id-type="pmid">22632725</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000e1;z</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Transplant-mediated enhancement of spinal cord GABAergic inhibition reverses paclitaxel-induced mechanical and heat hypersensitivity</article-title><source>Pain</source><year>2015</year><volume>156</volume><fpage>1084</fpage><lpage>1091</lpage><?supplied-pmid 25760475?><pub-id pub-id-type="pmid">25760475</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Shigemoto-Mogami</surname><given-names>Y</given-names></name><name><surname>Koizumi</surname><given-names>S</given-names></name><etal/></person-group><article-title>P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury</article-title><source>Nature</source><year>2003</year><volume>424</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1038/nature01786</pub-id><?supplied-pmid 12917686?><pub-id pub-id-type="pmid">12917686</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coull</surname><given-names>JAM</given-names></name><name><surname>Beggs</surname><given-names>S</given-names></name><name><surname>Boudreau</surname><given-names>D</given-names></name><etal/></person-group><article-title>BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>1017</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1038/nature04223</pub-id><?supplied-pmid 16355225?><pub-id pub-id-type="pmid">16355225</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>C</given-names></name></person-group><article-title>BDNF-induced TrkB activation down-regulates the K<sup>+</sup>&#x02013;Cl<sup>&#x02212;</sup> cotransporter KCC2 and impairs neuronal Cl<sup>&#x02212;</sup> extrusion</article-title><source>J Cell Biol</source><year>2002</year><volume>159</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1083/jcb.200209011</pub-id><?supplied-pmid 12473684?><pub-id pub-id-type="pmid">12473684</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coull</surname><given-names>JAM</given-names></name><name><surname>Boudreau</surname><given-names>D</given-names></name><name><surname>Bachand</surname><given-names>K</given-names></name><etal/></person-group><article-title>Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain</article-title><source>Nature</source><year>2003</year><volume>424</volume><fpage>938</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/nature01868</pub-id><?supplied-pmid 12931188?><pub-id pub-id-type="pmid">12931188</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>M</given-names></name><name><surname>Bergeron</surname><given-names>MJ</given-names></name><name><surname>Lavertu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Chloride extrusion enhancers as novel therapeutics for neurological diseases</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>1524</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1038/nm.3356</pub-id><?supplied-pmid 24097188?><pub-id pub-id-type="pmid">24097188</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandk&#x000fc;hler</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name></person-group><article-title>How to erase memory traces of pain and fear</article-title><source>Trends Neurosci</source><year>2013</year><volume>36</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2013.03.004</pub-id><?supplied-pmid 23602194?><pub-id pub-id-type="pmid">23602194</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Heinke</surname><given-names>B</given-names></name><name><surname>Ruscheweyh</surname><given-names>R</given-names></name><name><surname>Sandk&#x000fc;hler</surname><given-names>J</given-names></name></person-group><article-title>Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>1237</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1126/science.1080659</pub-id><?supplied-pmid 12595694?><pub-id pub-id-type="pmid">12595694</pub-id></element-citation></ref></ref-list></back></article>